Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials

Polymorphisms of GLP-1 Receptor Gene and Response to GLP-1 Analogue in Patients with Poorly Controlled Type 2 Diabetes

(2015) Chia-Hung Lin et al.   Journal of Diabetes Research

Trends in Prevalence and Control of Diabetes in the United States, 1988–1994 and 1999–2010

(2014) Elizabeth Selvin et al.   ANNALS OF INTERNAL MEDICINE

Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin

(2014) Heike Zimdahl et al.   DIABETOLOGIA

A comparison of type 2 diabetes risk allele load between African Americans and European Americans

(2014) Jacob M. Keaton et al.   HUMAN GENETICS

Meta-Analysis of Genome-Wide Association Studies in African Americans Provides Insights into the Genetic Architecture of Type 2 Diabetes

(2014) Maggie C. Y. Ng et al.   PLoS Genetics

Untangling the interplay of genetic and metabolic influences on beta-cell function: Examples of potential therapeutic implications involving TCF7L2 and FFAR1

(2014) Robert Wagner et al.   Molecular Metabolism

Large-Scale Gene-Centric Meta-Analysis across 39 Studies Identifies Type 2 Diabetes Loci

(2012) Richa Saxena et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Transferability and Fine Mapping of Type 2 Diabetes Loci in African Americans: The Candidate Gene Association Resource Plus Study

(2012) M. C. Y. Ng et al.   DIABETES

The Wnt Signaling Pathway Effector TCF7L2 Controls Gut and Brain Proglucagon Gene Expression and Glucose Homeostasis

(2012) W. Shao et al.   DIABETES

Genetic Risk Assessment of Type 2 Diabetes-Associated Polymorphisms in African Americans

(2012) J. N. Cooke et al.   DIABETES CARE

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction

(2012) Sheldon Russell   International Journal of Clinical Pharmacy

Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?

(2011) Robert H. Eckel et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

(2010) Richard E Pratley et al.   LANCET

Incretin-Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects

(2010) Scott R Drab   PHARMACOTHERAPY

TCF7L2 Variant rs7903146 Affects the Risk of Type 2 Diabetes by Modulating Incretin Action

(2009) D. T. Villareal et al.   DIABETES

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

(2009) B. Zinman et al.   DIABETES CARE

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

(2009) M. Marre et al.   DIABETIC MEDICINE

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

(2009) D. Russell-Jones et al.   DIABETOLOGIA

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Views on Personalized Medicine: Do the Attitudes of African American and White Prescription Drug Consumers Differ?

(2009) M. De Marco   Public Health Genomics

New treatments in type 2 diabetes: a focus on the incretin-based therapies

(2008) Anthony H. Barnett   CLINICAL ENDOCRINOLOGY

Racial Disparity in Glucagon-Like Peptide 1 and Inflammation Markers Among Severely Obese Adolescents

(2008) P. A. Velasquez-Mieyer et al.   DIABETES CARE

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

(2008) Alan Garber et al.   LANCET